Denali Therapeutics Inc (DNLI)
EBITDA Growth
-3.19%
Quarterly · Period ending:
DNLI EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-3.19%period ending
Latest reported-3.19%period ending
DNLI Quarterly EBITDA YoY % (-15.64% → -3.19%)
Year-over-year change
High-resolution chart · PNG
DNLI ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| -3.1899% | |
| 3.2029% | |
| -11.2425% | |
| -17.2669% | |
| -24.6745% | |
| 0.2552% | |
| 4.4344% | |
| -8.0166% | |
| -152.289% | |
| -30.437% | |
| -23.969% | |
| 3.976% | |
| 427.4857% | |
| -57.9544% | |
| -28.2756% | |
| -22.7631% | |
| 3.0639% | |
| 8.6396% | |
| -129.9522% | |
| -42.1687% | |
| 1.0908% | |
| -19.4511% | |
| 541.9852% | |
| -20.087% | |
| 3.2526% | |
| -44.2663% | |
| -172.2468% | |
| -35.4351% | |
| -10.0726% | |
| -61.1031% | |
| 439.1589% | |
| -65.6764% | |
| -154.6876% | |
| -18.4695% | |
| -19.0833% | |
| 14.7477% | |
| -19.9791% | |
| -15.6371% |